# Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)

> **NCT06005350** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Charite University, Berlin, Germany** · enrollment: 54 (estimated)

## Conditions studied

- NAD

## Interventions

- **DIETARY_SUPPLEMENT:** Niagen
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06005350
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06005350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06005350, "Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06005350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*